16 (23.5%), 6 (8.8%) and 2 (2.9%) patients received one, two and three additional lines of chemotherapy with or without anti-vascular endothelial growth factor (anti-VEGF) therapy before plasma and/or tumor re-biopsy for acquired T790M mutation. The gene discussed is VEGFA; the disease is neoplasm.